Am J Transplant, Volume 19, Suppl 3 Archives - Page 86 of 214 - ATC Abstracts

2019 American Transplant Congress
Symptom Burden after Living Donor Kidney Transplant Measured with the Functional Assessment of Cancer Therapy – Kidney Symptom Index is Associated with Worse Transplant Outcomes
J. Peipert, J. Caicedo-Ramirez, K. Ensor, J. Friedewald, M. Abecassis, D. Cella, D. Ladner, Z. Butt
Northwestern University, Chicago, IL
*Purpose: As the FDA and other stakeholders in transplantation look for fit-for-purpose (FFP) patient-reported outcome measures, there is a need to better understand symptom burden…
2019 American Transplant Congress
Donor-Derived Cell-Free DNA is Associated Specifically with Antibody Mediated Injury in Patients with Renal Allograft Dysfunction
B. Obrisca¹, C. Blosser², I. De Castro², C. Johnson², B. Sorohan¹, L. Sibulesky², R. Bakthavatsalam², G. Ismail¹, N. Leca²
¹Fundeni Clinical Institute, Bucharest, Romania, ²University of Washington, Seattle, WA
*Purpose: Donor-derived cell-free DNA (dd-cfDNA) has been proposed as a noninvasive biomarker to differentiate rejection from other types of injury in renal allografts.*Methods: We analyzed…
2019 American Transplant Congress
The Impact of Calcineurin Inhibitors on De Novo DSA in Primary Kidney Transplantation
T. Hiramitsu, T. Tomosugi, K. Futamura, M. Okada, M. Tsujita, T. Ichimori, N. Goto, S. Narumi, Y. Watarai
Nagoya Daini Red Cross Hospital, Nagoya Aichi, Japan
*Purpose: De novo DSA was demonstrated as a cause of chronic AMR, leading to worse graft survival. New strategies to treat chronic AMR have been…
2019 American Transplant Congress
ilearnKAS: An Animated Video to Educate African Americans about Key Concepts of Kidney Allocation
J. Narvaez, B. Dolph, T. Feeley, L. Kayler
University at Buffalo, Buffalo, NY
*Purpose: ilearnKAS is a iteratively-designed patient-engaged mobile educational animated video developed with guidance from patients, providers, Self-efficacy and Multimedia Learning Theories designed for African American…
2019 American Transplant Congress
Tacrolimus Concentration/Dose Ratio is an Independent Predictor of Death-Censored Kidney Allograft Survival
T. Jouve¹, J. Noble¹, X. Fonrose², B. Janbon¹, G. Fiard³, P. Malvezzi¹, L. Rostaing¹
¹Nephrology, Dialysis, Aphereses and Transplantation Department, Grenoble University Hospital, Grenoble, France, ²Pharmacology, Pharmacogenetics and Toxicology Laboratory, Grenoble University Hospital, Grenoble, France, ³Urology and Kidney Transplantation Department, Grenoble University Hospital, Grenoble, France
*Purpose: Tacrolimus (Tac) remains the cornerstone of kidney transplantation immunosuppression. Its narrow therapeutic index demands therapeutic drug monitoring. The C/D ratio (Tac trough concentration /…
2019 American Transplant Congress
Early Tacrolimus Trough Attainment in De Novo Kidney Transplant Recipients Treated with LCP-Tacrolimus (LCPT) vs. Immediate-Release Tacrolimus (IR-Tac)
K. Budde¹, S. Bunnapradist², S. J. Patel³, D. R. Stevens³, U. Meier-Kriesche³, B. Suwelack⁴
¹Charité University Medicine Berlin, Berlin, Germany, ²UCLA Medical Center, Los Angeles, CA, ³Veloxis Pharmaceuticals Inc., Cary, NC, ⁴University Hospital of Münster, Münster, Germany
*Purpose: Early achievement of therapeutic tacrolimus concentrations has been associated with reduced rates of acute rejection. A prospective, randomized, controlled study demonstrated safe and efficacious…
2019 American Transplant Congress
Relationship between Comorbilities and Infectious Disease in Kidney Transplant Recipients Receiving Rituximab
A. Molina-Andújar¹, E. Hermida¹, J. Rovira², F. Cofan¹, P. Ventura-Aguiar¹, N. Esforzado¹, V. Torregrosa¹, D. Cucchiari¹, E. de Souza¹, I. Revuelta¹, F. Oppenheimer¹, F. Diekmann¹, G. Piñeiro¹
¹Renal Transplant Unit, Hospital Clínic de Barcelona, Barcelona, Spain, ²Laboratori Experimental de Nefrologia i Trasplantament, IDIBAPS, Barcelona, Spain
*Purpose: Rituximab is commonly used in the context of kidney transplantation. Evidence about infectious complications and its relationship with predictive factors is scarce. The aim…
2019 American Transplant Congress
Urinary Biomarkers of Kidney Injury in Liver Transplant Recipients with Calcineurin Inhibitors Based Immunosuppression
D. Maluf¹, V. Bontha¹, A. Bajwa², A. Abdelaal¹, C. Koo¹, J. D. Eason², V. Mas²
¹UTHSC, Memphis, TN, ²Transplant Institute, Memphis, TN
*Purpose: Renal dysfunction post solid organ transplantation is common and associated with several risk factors. Messenger RNA encoding for genes expressed along the nephron and…
2019 American Transplant Congress
Renal Failure after Liver Transplantation: Benefits from a Little Pinch of KALT
R. Ruiz¹, K. Holmes², G. McKenna¹, N. Onaca¹, G. Testa¹, H. Fernandez¹, J. Bayer¹, A. Wall¹, E. Martinez¹, E. Martinez¹, A. Gupta¹, R. Goldstein¹, G. Klintmalm¹
¹Baylor All Saints Medical Center, Fort Worth, TX, ²Medical City Fort Worth, Fort Worth, TX
*Purpose: The development and consequences of renal failure after liver transplantation (LT) are well-chronicled. Kidney after liver transplantation (KALT) is the preferred treatment in this…
2019 American Transplant Congress
Functional Measures of Frailty and Not Sarcopenia Predict Mortality in a Prospective Cohort of Liver Transplant Candidates
R. Sharma, R. Rosenblatt, R. Knotts, J. Pisa, E. Verna
Division of Liver Diseases and Transplantation, Columbia Univeristy Medical Center, New York, NY
*Purpose: Sarcopenia determined by single slice measures of abdominal imaging have been correlated with liver transplant (LT) outcomes. However, in end-stage liver disease (ESLD), these…